Compass Therapeutics Inc (NASDAQ: CMPX) stock jumped 6.00% on Friday to $1.59 against a previous-day closing price of $1.50. With 0.86 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.26 million shares. The 52-week range on CMPX shows that it touched its highest point at $5.65 and its lowest point at $1.39 during that stretch. It currently has a 1-year price target of $9.17. Beta for the stock currently stands at 0.38.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CMPX was up-trending over the past week, with a rise of 2.58%, but this was down by -17.62% over a month. Three-month performance dropped to -32.63% while six-month performance fell -49.84%. The stock lost -64.67% in the past year, while it has lost -68.39% so far this year. A look at the trailing 12-month EPS for CMPX yields -0.33 with Next year EPS estimates of -0.44. For the next quarter, that number is -0.09. This implies an EPS growth rate of 10.04% for this year and -32.62% for next year.
Float and Shares Shorts:
At present, 126.30 million CMPX shares are outstanding with a float of 81.72 million shares on hand for trading. On Oct 30, 2023, short shares totaled 2.85 million, which was 2.24% higher than short shares on Sep 28, 2023. In addition to Dr. Thomas J. Schuetz M.D., Ph.D. as the firm’s Co-Founder, CEO & Director, Dr. Vered Bisker-Leib M.D., MBA, Ph.D. serves as its President & COO.
Institutional Ownership:
Through their ownership of 64.96% of CMPX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 32.80% of CMPX, in contrast to 21.75% held by mutual funds. Shares owned by individuals account for 12.37%. As the largest shareholder in CMPX with 5.19% of the stake, Janus Henderson Investors US LLC holds 6,615,938 shares worth 6,615,938. A second-largest stockholder of CMPX, Adage Capital Management LP, holds 6,380,000 shares, controlling over 5.01% of the firm’s shares. Braidwell LP is the third largest shareholder in CMPX, holding 5,954,273 shares or 4.67% stake. With a 2.80% stake in CMPX, the Biotech Growth Trust Plc is the largest stakeholder. A total of 3,571,428 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 1.72% of CMPX stock, is the second-largest Mutual Fund holder. It holds 2,187,972 shares valued at 3.94 million. iShares Russell 2000 ETF holds 1.61% of the stake in CMPX, owning 2,052,408 shares worth 3.69 million.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CMPX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With CMPX analysts setting a high price target of $11.00 and a low target of $8.00, the average target price over the next 12 months is $9.17. Based on these targets, CMPX could surge 591.82% to reach the target high and rise by 403.14% to reach the target low. Reaching the average price target will result in a growth of 476.73% from current levels.
Summary of Insider Activity:
Insiders traded CMPX stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 7 while that of sell transactions has risen to 4 over the past year. The total number of shares bought during that period was 990,000 while 40,535 shares were sold.
